In pancreatic cancer, MUC16 can be combined with Mesothelin to increase the expression of matrix metalloproteinase-7 (MMP7) by increasing the phosphorylation of p38 mitogen-activated protein kinase (MAPK) (but not changing the total p38 level) to promote the movement and invasion of pancreatic cancer cells (Fig. 3) [50]. Here, MSLN is linked to pancreatic neoplasm.